Ganguly S

ORCID: 0000-0002-3037-1959 · 2 papers in corpus

2024

Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.

BMJ open ·doi:10.1136/bmjopen-2024-087431

ObjectivePregnant women with COVID-19 are at elevated risk for severe outcomes, but clinical data on management of these patients are limited. Monoclonal antibodies, such as casirivimab plus imdevimab (CAS+IMD), have proven effective in tre…

2024

The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.

Frontiers in immunology ·doi:10.3389/fimmu.2024.1441730

In recent years, immunotherapy has emerged as a crucial component of cancer treatment. However, its efficacy remains limited across various cancer types, highlighting unmet needs. Poliovirus receptor-related 2 (PVRL2) and Poliovirus recepto…